HC Wainwright Reiterates “Buy” Rating for Voyager Therapeutics (NASDAQ:VYGR)

HC Wainwright reaffirmed their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock.

Several other analysts have also recently issued reports on VYGR. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Wedbush restated an “outperform” rating and set a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a report on Tuesday, February 11th. Finally, Citigroup started coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $15.72.

Voyager Therapeutics Trading Up 4.8 %

NASDAQ:VYGR opened at $4.15 on Monday. Voyager Therapeutics has a 12-month low of $3.80 and a 12-month high of $10.66. The stock has a 50-day moving average price of $5.11 and a 200 day moving average price of $5.97. The stock has a market capitalization of $226.70 million, a P/E ratio of 5.85 and a beta of 0.99.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Vestal Point Capital LP raised its position in shares of Voyager Therapeutics by 151.0% in the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company’s stock worth $6,974,000 after acquiring an additional 740,000 shares in the last quarter. Virtus Investment Advisers Inc. grew its stake in Voyager Therapeutics by 59.0% during the 4th quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company’s stock worth $114,000 after buying an additional 7,457 shares during the last quarter. Tema Etfs LLC purchased a new position in Voyager Therapeutics during the 4th quarter worth $85,000. Man Group plc purchased a new position in Voyager Therapeutics during the 4th quarter worth $234,000. Finally, Farallon Capital Management LLC grew its stake in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company’s stock worth $14,576,000 after buying an additional 278,700 shares during the last quarter. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.